Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Sandrine Niyongere"'
Autor:
Amy E. DeZern, Alan F. List, Jeffrey E. Lancet, Hannah Newman, Eric Padron, Maria E. Balasis, Mikkael A. Sekeres, Rami S. Komrokji, Anthony M. Hunter, Qianxing Mo, Traci Kruer, Sandrine Niyongere, Markus Ball, Christopher Letson, Aaron T. Gerds, Gail J. Roboz, David A. Sallman, Hailing Zhang, Onyee Chan, David P. Steensma, William Dominguez-Viqueira
Publikováno v:
Clinical Cancer Research. 27:6095-6105
Purpose: Chronic myelomonocytic leukemia (CMML) is a rare leukemia characterized by peripheral monocytosis with no disease-modifying therapies. CMML cells are uniquely hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) and ro
Autor:
Jonathan Cornu, Vu H. Duong, Alison Duffy, Maria R. Baer, Sandrine Niyongere, Jummai Apata, Ciera L Patzke, Noa G. Holtzman, Sarah M. Kashanian, Ashkan Emadi, Farin Kamangar, Madhurima Koka
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:817-826
Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL
Autor:
Maria R. Baer, Amol C. Shetty, Elizabeth T. Chang, Sandrine Niyongere, Erin T. Strovel, Rena G. Lapidus, Ronald B. Gartenhaus, Kayla M. Tighe, Bandish Kapadia, Brandon Carter-Cooper, Ashkan Emadi, Anup Mahurkar, Farin Kamangar, Binny Bhandary, Dominique R Bollino, Xinrong Ma, Eun Yong Choi, Curt I. Civin, Blake S. Moses, Hannah Kaizer
Publikováno v:
Leukemia. 35:1907-1924
Complex karyotype acute myeloid leukemia (CK-AML) has a dismal outcome with current treatments, underscoring the need for new therapies. Here, we report synergistic anti-leukemic activity of the BCL-2 inhibitor venetoclax (Ven) and the asparaginase f
Autor:
Max An, Justin Lawson, Muhammad Safwan, Sandrine Niyongere, Maria R. Baer, Tahreem Iqbal, Vu H. Duong, Jennie Y. Law, Brian Barr, Gabriela Sanchez-Petitto, Michael E. Kallen, Ashkan Emadi, James Childress, Madhurima Koka, Jack Masur, Olga Goloubeva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S350-S351
Context: The incidence of both myeloid malignancies and cardiovascular disease (CVD) increases with age. We aimed to study whether the presence of CVD is associated with worse outcomes in patients with myeloid malignancies and to delineate a possible
Autor:
Aaron P. Rapoport, Sandrine Niyongere
Publikováno v:
Haematologica
We have developed a personalized vaccine whereby patient derived leukemia cells are fused to autologous dendritic cells, evoking a polyclonal T cell response against shared and neo-antigens. We postulated that the dendritic cell (DC)/AML fusion vacci
Autor:
Sandrine Niyongere, Maria R. Baer, Gabriela Sanchez-Petitto, Jack Masur, Vu H. Duong, Ashkan Emadi
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 13, Iss 124, p 124 (2020)
Pharmaceuticals, Vol 13, Iss 124, p 124 (2020)
Outcomes of acute lymphoblastic leukemia (ALL) in older adults treated with chemotherapy are poor. The CD19/CD3 bispecific T-cell engager (BiTE) antibody blinatumomab is approved for refractory, relapsed or minimal/measurable residual disease (MRD)-p
Autor:
Sandrine Niyongere, Michael W. Deininger, Brooke L. Fridley, Qing Zhang, Yu Long Zhao, John Robinson, Samer S. Sansil, Eric Padron, Rami S. Komrokji, Eric Solary, Alan F. List, Markus Ball, Valeria Santini, Junmin Zhou, Jodi L. Kroeger, Anthony D. Pomicter, Maria E. Balasis, Nolwenn Lucas
Publikováno v:
Leukemia
Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous neoplasm in which JAK2 inhibition has demonstrated reductions in inflammatory cytokines and promising clinical activity. We hypothesize that annotation of inflammatory cytokines may
Publikováno v:
Journal of Thoracic Disease. 10:S433-S450
Immune checkpoint inhibitors enhance the activation and antitumor activity of the immune system, resulting in durable response rates in a select group of patients. Cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitors target the inhibitory interaction
Autor:
Elizabeth M. Corley, Moaath Mustafa Ali, Ashkan Emadi, Kathryn V. Kline, Danielle Sewell, Vu H. Duong, Sandrine Niyongere, Jennie Y. Law, Maria R. Baer, Seung Tae Lee, Hanan Alharthy
Publikováno v:
Blood. 138:4454-4454
Introduction Mutations have become essential in determining risk stratification for acute myeloid leukemia (AML) and are often used to guide treatment. Variants of unknown significance (VUS) can be classified as pathogenic or benign once their roles
Autor:
Dominique R Bollino, Rena G. Lapidus, Maria R. Baer, Veronica Kflu, Jinoos Zarrabi, Osman Mohamed Bah, Sunita Philip, Sandrine Niyongere, Erin T. Strovel, Ashkan Emadi, Vu H. Duong
Publikováno v:
Blood. 138:4433-4433
Background: Despite new therapeutic advances, acute myeloid leukemia (AML) still has poor outcomes, especially in patients with relapsed or refractory (R/R) disease with complex karyotype (CK) and/or TP53 mutation. Venetoclax (Ven), an oral BCL-2 inh